Ultimately, the decision to continue or discontinue GLP-1 therapy should be individualized, considering treatment response, tolerability, patient preferences, cost, and overall health status
Oral semaglutide was then investigated in eight global Peptide InnOvatioN for the Early diabEtes tReatment (PIONEER) phase IIIa trials in over 8,000 patients, with similarly broad evaluation in different patient populations who were receiving a range of background medications ( Table 1 )
Elahi D, Egan JM, Shannon RP et al (2008) GLP-1 (936) amide, cleavage product of GLP-1 (736) amide, is a glucoregulatory peptide
Check your insurance policy or speak with a provider to clarify your plans coverage
A global and stratified analysis according to the therapeutic scheme used was performed using the fixed-effects model